NR1H4 and kidney disorder: Drugs that act on the arachidonic acid soluble epoxide hydrolase (sEH) enzyme combined with PPARγ and FXR agonism have been developed to treat cardiovascular diseases, diabetes, and kidney diseases (Imig et al., 2021; Lillich et al., 2021).